Aspira Women's Health (AWH) 10-Q 13 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	VERMILLION, INC.
Entity Central Index Key	926,617
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		51,964,375

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 10,878	$ 22,965
Accounts receivable	165	167
Prepaid expenses and other current assets	667	526
Total current assets	11,710	23,658
Property and equipment, net	535	508
Other assets	90	8
Total assets	12,335	24,174
Current liabilities:
Accounts payable	533	1,123
Accrued liabilities	2,581	2,201
Short-term debt		1,106
Deferred revenue		489
Total liabilities	$ 3,114	$ 4,919
Commitments and contingencies (Note 3)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding at June 30, 2015 and December 31, 2014, respectively
Common stock, $0.001 par value, 150,000,000 shares authorized at June 30, 2015 and December 31, 2014; 42,271,192 and 43,115,790 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	$ 42	$ 43
Additional paid-in capital	369,638	370,685
Accumulated deficit	(360,459)	(351,473)
Total stockholders' equity	9,221	19,255
Total liabilities and stockholders' equity	$ 12,335	$ 24,174

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	42,271,192	43,115,790
Common stock, shares outstanding	42,271,192	43,115,790

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Product		$ 535	$ 211	$ 1,170	$ 402
License			113	316	227
Total revenue		535	324	1,486	629
Cost of revenue:
Product		574	88	1,065	143
Total cost of revenue		574	88	1,065	143
Gross profit		(39)	236	421	486
Operating expenses:
Research and development	[1]	919	1,057	2,024	2,210
Sales and marketing	[2]	2,559	2,766	4,776	4,870
General and administrative	[3]	1,331	1,971	2,731	2,959
Total operating expenses		4,809	5,794	9,531	10,039
Loss from operations		(4,848)	(5,558)	(9,110)	(9,553)
Interest income		6	12	15	26
Other income (expense), net		(7)	(9)	109	(15)
Net loss		$ (4,849)	$ (5,555)	$ (8,986)	$ (9,542)
Net loss per share - basic and diluted		$ (0.11)	$ (0.15)	$ (0.21)	$ (0.27)
Weighted average common shares used to compute basic and diluted net loss per common share		42,985,954	35,853,027	43,050,872	35,840,491
[1]	(1) Research and development$ 32$ 31$ 63$ 71
[2]	(2) Sales and marketing 36 44 73 69
[3]	(3) General and administrative 131 290 228 359

Consolidated Statements Of Ope5

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research And Development [Member]
Stock-based compensation expense	$ 32	$ 31	$ 63	$ 71
Sales And Marketing [Member]
Stock-based compensation expense	36	44	73	69
General And Administrative [Member]
Stock-based compensation expense	$ 131	$ 290	$ 228	$ 359

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (8,986)	$ (9,542)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt	(78)
Non-cash license revenue	(316)	(227)
Depreciation and amortization	113	58
Stock-based compensation expense	363	479
Warrants issued for services		20
Changes in operating assets and liabilities:
Accounts receivable	2	183
Prepaid expenses and other assets	(223)	(347)
Accounts payable, accrued liabilities and other liabilities	(169)	1,536
Deferred revenue	(173)	586
Net cash used in operating activities	(9,467)	(7,254)
Cash flows from investing activities:
Purchase of property and equipment	(140)	(83)
Net cash used in investing activities	(140)	(83)
Cash flows from financing activities:
Repurchase of common stock	(1,291)
Issuance costs from sale of common stock and warrants	(122)
Repayment of short-term debt	(1,069)
Proceeds from issuance of common stock from exercise of stock options	2	19
Net cash (used in) provided by financing activities	(2,480)	19
Net decrease in cash and cash equivalents	(12,087)	(7,318)
Cash and cash equivalents, beginning of period	22,965	29,504
Cash and cash equivalents, end of period	$ 10,878	$ 22,186

Organization, Basis Of Presenta

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	6 Months Ended
	Jun. 30, 2015
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies	1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. In March 2010, the Company commercially launched OVA1™ risk of malignancy test for pelvic mass disease (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 2) and through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”), which opened i n June 2014. Liquidity On July 17, 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares in an underwritten public offering at a price of $1.96 per share. The Company expects net proceeds from the offering will be approximately $17,500,000 after deducting underwriting discounts and offering expenses. The Company’s management believes that the Company’s working capital position as of the date of the filing of this Quarterly Report on Form 10-Q, including the net proceeds from the July 2015 public offering, will be sufficient to meet the Company’s working capital needs for at least the next 12 months. However, the Company expects cash for OVA1 tests to be its only material, recurring source of cash in 2015. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. In addition, there is no assurance of the Company’s ability to generate substantial revenues and cash flows from ASPiRA LABS’ operations. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2014 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014, included in Vermillion’s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 31, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Certain reclassifications of prior year amounts have been made to conform to current year presentation. Significant Accounting and Reporting Policies The Company has made no significant changes in its critical accounting policies and estimates from those disclosed in Vermillion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 .

Agreements with Quest Diagnosti

Agreements with Quest Diagnostics Incorporated	6 Months Ended
	Jun. 30, 2015
Agreements With Quest Diagnostics Incorporated [Abstract]
Agreements With Quest Diagnostics Incorporated	2. AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED In July 2005, the Company entered into a Strategic Alliance Agreement (as amended, the “Strategic Alliance Agreement”) with Quest Diagnostics to develop and commercialize diagnostic tests, including OVA1, from the Company’s product pipeline. In connection with the Strategic Alliance Agreement, the Company entered into a credit agreement with Quest Diagnostics, pursuant to which Quest Diagnostics provided the Company with a $10,000,000 secured line of credit to be used to pay for certain costs and expenses related to activities under the Strategic Alliance Agreement. This line of credit was collateralized by certain of the Company’s intellectual property assets. The credit agreement provided for the forgiveness of portions of the amounts borrowed under the secured line of credit upon the achievement of certain milestones related to the development, regulatory approval and commercialization of certain diagnostic tests. Through December 31, 2014, the entire loan was either repaid or forgiven except for $1,106,000 which was in dispute. The dispute regarding the balance of the loan was resolved on March 11, 2015 for a payment to Quest Diagnostics totaling $1,069,000 . As a result of this settlement, the Company recognized one-time items during the three months ended March 31, 2015, including product revenue of $163,000 , license revenue of $202,000 , gain on extinguishment of debt of $78,000 and reversal of other liabilities totaling $37,000 . Unrelated to the debt dispute described above, in August 2013, the Company sent Quest Diagnostics a notice of termination of the Strategic Alliance Agreement. Notwithstanding the termination, the Company agreed that Quest Diagnostics could continue to make OVA1 available to healthcare providers on the same financial terms following the termination while negotiating in good faith towards an alternative business structure. Quest Diagnostics disputed the effectiveness of the termination. Prior to the termination, Quest Diagnostics had the non-exclusive right to commercialize OVA1 on a worldwide basis, with exclusive commercialization rights in the clinical reference laboratory marketplace in the United States, India, Mexico, and the United Kingdom through September 2014, with the right to extend the exclusivity period for one additional year. O n March 11, 2015, the Company reached a settlement agreement with Quest Diagnostics that terminated all disputes related to the Strategic Alliance Agreement and the Company’s prior loan agreement with Quest Diagnostics. The Company also entered into a new commercial agreement with Quest Diagnostics. Pursuant to this agreement, substantially all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion’s wholly-owned subsidiary, ASPiRA LABS, as of August 10, 2015 . The Company expects Quest Diagnostics to transfer all remaining OVA1 U.S. testing services to ASPiRA LABS during 2015 while continuing to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2017 . Quest Diagnostics will receive a fee for collection and logistic support services it provides. Per the terms of the new commercial agreement , the Company will not offer to existing or future Quest Diagnostics customers CA 125-II or other tests that Quest Diagnostics offers. On June 17, 2015, the Company entered into a Share Repurchase Agreement (the “ Share Repurchase Agreement ”) with Quest Diagnostics. Pursuant to the Share Repurchase Agreement, the Company purchased from Quest Diagnostics 860,595 shares of Vermillion common stock for a total purchase price of $1,290,892 , or $1.50 per share. The price per share was agreed to in principle in March 2015 and based upon a simple average of the closing prices per share of Vermillion common stock for a trailing 60 -day period at that time. This price was then reduced by a negotiated discount. Subsequently, the common stock repurchased from Quest Diagnostics was retired. Accounts receivable from Quest Diagnostics under the Strategic Alliance Agreement totaled $165,000 and $167,000 at June 30 , 2015 and December 31, 2014, respectively.

Commitments And Contingencies

Commitments And Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies [Abstract]
Commitments And Contingencies	3. COMMITMENT AND CONTINGENCIES The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease , including its principal facility and CLIA laboratory located near Austin, Texas. The leases include an aggregate annual base rent of $130,000 and annual estimated common area charges, taxes and insurance of $62,000 and expire at various times prior to May 31, 2016 . In April 2015, the Company agreed to purchase two laboratory instruments for a total initial payment of $250,000 and ongoing payments of approximately $7,000 per month for 36 months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	4. STOCKHOLDERS’ EQUITY 2010 Stock Incentive Plan The Company’s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan (the “2010 Plan”). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to 8,122,983 shares of Vermillion common stock under the 2010 Plan, subject to adjustment as provided in the 2010 Plan. Employee Stock-Based Compensation During the six months ended June 30, 2015, the Company granted to the Company’s President and Chief Executive Officer stock options to purchase 400,000 shares of Vermillion common stock with an exercise price of $1.95 per share. These stock options vest in 48 equal monthly installments from the date of the grant. The Company also granted to certain Vermillion officers options to purchase 275,000 shares of Vermillion common stock with an exercise price of $2.08 and granted to certain Vermillion employees options to purchase 45,000 shares of Vermillion common stock with an exercise price of $1.77 . These stock options vest 25% on the first anniversary of the grant date, and the remaining stock options vest ratably over the following 36 -month period. During the six months ended June 30, 2015, the Company granted to a Vermillion officer options to purchase 150,000 shares of Vermillion common stock with an exercise price of $1.74 per share. These stock options vest 25% on the first anniversary of the grant date, and the remaining stock options vest ratably over the following 36 -month period. Subsequent to June 30, 2015, the Company granted to officers and employees of the Company stock options to purchase 317,000 shares of Vermillion common stock with an exercise price of $2.03 per share. These stock options vest 25% on each of the four anniversaries of the grant date. In addition, subsequent to June 30, 2015, the Company granted certain officers stock options to purchase 400,000 shares of Vermillion common stock with an exercise price of $2.03 per share with performance-based vesting based on metrics through December 31, 2016. During the six months ended June 30, 2015, the Company awarded 181,369 shares of restricted stock under the 2010 Plan having a fair value of approximately $370,000 to Vermillion’s Board of Directors as stock-based payment for services rendered in 2015. These shares of restricted stock vested 50% on July 13, 2015, and the remainder will vest 25% on each of September 1, 2015 and December 1, 2015. The allocation of employee stock-based compensation expense by functional area for the three and six months ended June 30 , 2015 and 2014 was as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2015 2014 2015 2014 Research and development $ $ $ $ Sales and marketing General and administrative Total $ $ $ $

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2015
Loss Per Share [Abstract]
Loss Per Share	5 . LOSS PER SHARE The Company calculates basic loss per share using the weighted average number of common shares outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the weighted average number of shares of common stock outstanding and excludes the effects of 7,163,329 and 2,922,619 potential shares of common stock as of June 30, 2015 and 2014, respectively, that are anti-dilutive. Potential shares of common stock include incremental shares of common stock issuable upon the exercise of outstanding warrants and stock options.

Organization, Basis of Presen12

Organization, Basis of Presentation And Significant Accounting And Reporting Policies (Policy)	6 Months Ended
	Jun. 30, 2015
Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]
Organization	Organization Vermillion, Inc. (“Vermillion”; Vermillion and its wholly-owned subsidiaries are collectively referred to as the “Company”) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. In March 2010, the Company commercially launched OVA1™ risk of malignancy test for pelvic mass disease (“OVA1”). The Company distributes OVA1 through Quest Diagnostics Incorporated (“Quest Diagnostics”) (see Note 2) and through its wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, ASPiRA LABS, Inc. (“ASPiRA LABS”), which opened i n June 2014.
Liquidity	Liquidity On July 17, 2015 the Company completed the sale of 9,602,500 shares of Vermillion common stock, including 1,252,500 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares in an underwritten public offering at a price of $1.96 per share. The Company expects net proceeds from the offering will be approximately $17,500,000 after deducting underwriting discounts and offering expenses. The Company’s management believes that the Company’s working capital position as of the date of the filing of this Quarterly Report on Form 10-Q, including the net proceeds from the July 2015 public offering, will be sufficient to meet the Company’s working capital needs for at least the next 12 months. However, the Company expects cash for OVA1 tests to be its only material, recurring source of cash in 2015. There can be no assurance that the Company will achieve or sustain profitability or positive cash flow from operations. In addition, there is no assurance of the Company’s ability to generate substantial revenues and cash flows from ASPiRA LABS’ operations.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. The unaudited consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The consolidated balance sheet at December 31, 2014 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014, included in Vermillion’s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 31, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results. Certain reclassifications of prior year amounts have been made to conform to current year presentation.
Significant Accounting And Reporting Policies	Significant Accounting and Reporting Policies The Company has made no significant changes in its critical accounting policies and estimates from those disclosed in Vermillion’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity [Abstract]
Allocation of Stock-Based Compensation Expense by Functional Area	Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2015 2014 2015 2014 Research and development $ $ $ $ Sales and marketing General and administrative Total $ $ $ $

Organization, Basis Of Presen14

Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details) - USD ($)	Jul. 17, 2015	Jun. 30, 2015	Dec. 31, 2014
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued		42,271,192	43,115,790
Price per share		$ 0.001	$ 0.001
Subsequent Event
Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued	9,602,500
Shares issued to underwriters	1,252,500
Price per share	$ 1.96
Proceeds from sale of common stock, net of issuance costs	$ 17,500,000

Agreements With Quest Diagnos15

Agreements With Quest Diagnostics Incorporated (Details) - USD ($)	Jun. 17, 2015	Mar. 11, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Line of Credit Facility [Line Items]
Secured line of credit, liability								$ 1,106,000
Repayment of short-term debt						$ 1,069,000
Product			$ 535,000		$ 211,000	1,170,000	$ 402,000
License					$ 113,000	316,000	$ 227,000
Gain on extinguishment of debt						$ 78,000
Shares authorized for repurchase	$ 860,595
Total purchase price of shares acquired	$ 1,290,892
Shares acquired, price per share	$ 1.50
Trailing period						60 days
Quest Diagnostics [Member]
Line of Credit Facility [Line Items]
Quest Diagnostics provided secured line of credit			10,000,000			$ 10,000,000
Secured line of credit, liability								1,106,000
Repayment of short-term debt		$ 1,069,000
Product				$ 163,000
License				202,000
Gain on extinguishment of debt				78,000
Decrease to other current liabilities				$ 37,000
Accounts receivable from related party			$ 165,000			$ 165,000		$ 167,000

Commitments And Contingencies (

Commitments And Contingencies (Details)	1 Months Ended	6 Months Ended
	Apr. 30, 2015USD ($)item	Jun. 30, 2015USD ($)
Commitments And Contingencies [Abstract]
Annual base rent		$ 130,000
Annual estimated common area charges, taxes and insurance		$ 62,000
Lease expiration date		May 31, 2016
Number of purchased laboratory instruments | item	2
Initial payment of laboratory equipment	$ 250,000
Monthly payment for acquisition for equipment	$ 7,000
Number of payments for purchase production of assets		36 months

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	Aug. 13, 2015	Jun. 30, 2015	Jul. 17, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value		$ 0.001		$ 0.001
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value			$ 1.96
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant		8,122,983
2010 Stock Incentive Plan [Member] | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares awarded		181,369
Fair value of restricted shares awarded		$ 370
2010 Stock Incentive Plan [Member] | Restricted Stock | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		50.00%
2010 Stock Incentive Plan [Member] | Restricted Stock | Share-based Compensation Award, Tranche Two And Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		400,000
Stock options granted, average exercise price		$ 1.95
Stock options vesting period		48 months
2010 Stock Incentive Plan [Member] | Vermillion Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		275,000
Stock options granted, average exercise price		$ 2.08
2010 Stock Incentive Plan [Member] | Certain Vermillion Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		45,000
Stock options granted, average exercise price		$ 1.77
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options vesting period		36 months
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	317,000
Stock options granted, average exercise price	$ 2.03
2010 Stock Incentive Plan [Member] | Other Officers And Employees [Member] | Subsequent Event | Share-based Compensation Award, Tranche One Through Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
2010 Stock Incentive Plan [Member] | Certain Officers [Member] | Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	400,000
Stock options granted, average exercise price	$ 2.03
2010 Stock Incentive Plan [Member] | Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted		150,000
Stock options granted, average exercise price		$ 1.74
Stock options vesting period		36 months
2010 Stock Incentive Plan [Member] | Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage		25.00%

Stockholders' Equity (Allocatio

Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 32	$ 31	$ 63	$ 71
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	36	44	73	69
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	131	290	228	359
Employee Stock-Based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	199	365	364	499
Employee Stock-Based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	32	31	63	71
Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	36	44	73	69
Employee Stock-Based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 131	$ 290	$ 228	$ 359

Loss Per Share (Details)

Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Loss Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	7,163,329	2,922,619